MSFT   207.50 (+1.37%)
GOOGL   1,482.70 (+2.82%)
MU   50.20 (+1.01%)
GE   6.85 (+1.63%)
TSLA   1,202.26 (+7.38%)
T   30.36 (+1.50%)
ACB   12.05 (-1.79%)
F   6.09 (+1.84%)
GILD   76.59 (+0.70%)
BAC   23.50 (+1.03%)
MSFT   207.50 (+1.37%)
GOOGL   1,482.70 (+2.82%)
MU   50.20 (+1.01%)
GE   6.85 (+1.63%)
TSLA   1,202.26 (+7.38%)
T   30.36 (+1.50%)
ACB   12.05 (-1.79%)
F   6.09 (+1.84%)
GILD   76.59 (+0.70%)
BAC   23.50 (+1.03%)
MSFT   207.50 (+1.37%)
GOOGL   1,482.70 (+2.82%)
MU   50.20 (+1.01%)
GE   6.85 (+1.63%)
TSLA   1,202.26 (+7.38%)
T   30.36 (+1.50%)
ACB   12.05 (-1.79%)
F   6.09 (+1.84%)
GILD   76.59 (+0.70%)
BAC   23.50 (+1.03%)
MSFT   207.50 (+1.37%)
GOOGL   1,482.70 (+2.82%)
MU   50.20 (+1.01%)
GE   6.85 (+1.63%)
TSLA   1,202.26 (+7.38%)
T   30.36 (+1.50%)
ACB   12.05 (-1.79%)
F   6.09 (+1.84%)
GILD   76.59 (+0.70%)
BAC   23.50 (+1.03%)
Log in

NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News

$12.54
+0.42 (+3.47 %)
(As of 07/2/2020 02:10 PM ET)
Add
Compare
Today's Range
$12.14
Now: $12.54
$12.78
50-Day Range
$9.84
MA: $11.12
$12.90
52-Week Range
$5.61
Now: $12.54
$21.85
Volume3,796 shs
Average Volume205,441 shs
Market Capitalization$223.84 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
Kalvista Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.13 million
Book Value$5.61 per share

Profitability

Net Income$-20,820,000.00
Net Margins-263.38%

Miscellaneous

Employees33
Market Cap$223.84 million
Next Earnings Date9/14/2020 (Estimated)
OptionableNot Optionable

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has Kalvista Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 43.6% and is now trading at $12.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kalvista Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020. View our earnings forecast for Kalvista Pharmaceuticals.

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) issued its quarterly earnings data on Wednesday, July, 1st. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.28. The specialty pharmaceutical company had revenue of $3.82 million for the quarter, compared to analyst estimates of $2.05 million. Kalvista Pharmaceuticals had a negative return on equity of 32.17% and a negative net margin of 263.38%. View Kalvista Pharmaceuticals' earnings history.

What price target have analysts set for KALV?

4 brokers have issued 12-month target prices for Kalvista Pharmaceuticals' stock. Their forecasts range from $25.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals.

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

Headlines about KALV stock have trended very negative on Thursday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Kalvista Pharmaceuticals.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $12.72.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $227.05 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.